Pfizer to acquire FoldRx

Pfizer Inc. (NYSE:PFE) will acquire FoldRx Pharmaceuticals Inc. (Cambridge, Mass.) for an undisclosed upfront payment plus potential milestones. Pfizer gains FoldRx's lead candidate, tafamidis, a small molecule that stabilizes transthyretin (TTR) protein and prevents misfolding. The compound is under review in Europe to treat TTR amyloid polyneuropathy (ATTR-PN). Pfizer also gains FoldRx's yeast-based drug target discovery programs for cystic fibrosis (CF), Parkinson's disease (PD) and Huntington's disease (HD). ...